Boehringer, Zealand reframe diabetes pact

Share this article:

Boehringer Ingeleim and Zealand Pharma are still diabetes partners but have redefined the relationship they began in 2011.

The companies said in a joint statement that they will continue to collaborate on novel glucagon/GLP-1 dual agonists for diabetes or obesity, but ZP2929 is no longer the keystone compound.

Instead, Zealand gets all rights to ZP2929, and another agent will be swapped in. The companies said the original financial collaboration arrangements are staying put.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.